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The mitochondrial DNA depletion syndrome (MDDS) is characterized by ex-
tensive phenotypic variability and is due to nuclear gene mutations resulting in 
reduced mtDNA copy number. Thymidine kinase 2 (TK2) mutations are well 
known to be associated with MDDS. Few severely affected cases carrying the 
c.416C > T mutation in TK2 gene have been described so far. We describe the case 
of a 14months boy with the aforementioned TK2 gene pathogenic mutation at a 
homozygous state, presenting with a mild clinical phenotype. In addition to severe 
mitochondrial pathology on muscle biopsy, there was also histochemical evidence 
of adenylate deaminase deficiency. Overall, this report serves to further expand 
the clinical spectrum of TK2 mutations associated with MDDS.
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Introduction
Mitochondrial diseases are clinically and genetically heterogenous 
disorders due to respiratory chain disturbance with subsequent failure of 
aerobic metabolism, leading to dysfunction of multiple organs, especially 
the highly energy dependent. The pathogenic mutations may be either in 
the mitochondrial DNA (mtDNA) or in the nuclear DNA (nDNA), which 
encode mitochondrial proteins 1. Mitochondria are essentially the source 
of high-energy intermediates and are considered as the lever of cellular 
function. To fulfill their role, they have to constantly fuse and divide, pro-
cesses that are quite complex and dependent on mtDNA replisome en-
zymes, nucleotides supply and balanced mitochondrial dynamics. Defects 
in mtDNA replication may be due to any of the aforementioned stage, 
resulting in usually multisystemic disorders 1,2. 
Mitochondrial thymidine kinase (TK2) is the catalytic enzyme for the 
phosphorylation reaction of pyrimidine deoxyribonucleosides, which is 
the first step in the conversion of deoxynucleosides into deoxyribonucleo-
tide triphosphates (dNTPs) (2). Therefore, TK2-mutations are responsible 
for disorders of mtDNA nucleotides supply encompassing a broad pheno-
typic spectrum, with myopathy and progressive external ophthalmoplegia 
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(PEO) being some of the most prominent clinical char-
acteristics 2. The clinical variability of mtDNA depletion 
syndrome due to TK2-mutations may be partly related to 
the different extent of enzymatic activity, which is deter-
mined by the mutant gene 3. 
Herein, we describe a now 4-year-old boy, diagnosed 
at 14 months of age, with a mitochondrial DNA deple-
tion syndrome (MDDS) harboring a TK2 gene pathogenic 
mutation at a homozygous state with a milder phenotype 
than previously reported. 
Case report
The index patient, a boy aged 14-months on his first 
admission, was firstly investigated in the pediatric depart-
ment for persistently high creatine phosphokinase (CK) 
serum levels and mild transaminasemia, which were 
initially randomly detected. CK values (normal range 
0-180 U/L) fluctuated from 700 U/L up to a maximum 
of 17.870 U/L, without any evidence of myoglobinuria. 
The patient is the second child, born at term, to a 
healthy, non-consanguineous couple. His birth weight 
was 3.008 kg and he had a normal perinatal period and 
psychomotor development. His 4-yr old brother had an 
unremarkable medical history with just milk allergy. None 
of the patient’s relatives had increased CK and there was 
no family history for any neuromuscular disease. Clini-
cal examination, including muscle strength, muscle tone, 
tendon reflexes, cranial nerves and coordination, was nor-
mal. Although, the infant could sit and stand unsupported, 
he had not yet at that time achieved independent walking. 
With the exception of muscle enzymes, other laboratory 
tests, including virological markers and immunological 
parameters, were normal. Heart evaluation with ECG and 
echocardiogram did not reveal any abnormalities. Brain 
MRI was also normal. Genetic testing for deletions and 
duplications in the dystrophin gene was also normal. 
A vastus lateralis muscle biopsy revealed myopathic 
changes with abnormal variation of muscle fiber diameter 
and multiple cytochromoxidase-negative (COX-negative) 
muscle fibers with few ragged red (trichrome Gomori 
staining) and/or ragged blue (succinate dehydrogenase 
staining), confirming the diagnosis of mitochondrial 
myopathy (Fig. 1). Histochemistry showed also myoad-
enylate deaminase deficiency (Fig. 2). Biochemical anal-
ysis of the muscle biopsy revealed a combined deficiency 
involving complexes 1, III and IV, pointing either to a 
mtDNA mutation or a defect in the mitochondrial protein 
synthesis due to a nuclear gene mutation. 
Genomic DNA from muscle biopsy revealed an al-
ready known pathogenic mutation in the TK2 gene in ho-
mozygosity (NM_004614.5: c.416C > T, p.Ala139Val) 4,5, 
which was further confirmed by Sangers analysis. Both 
parents were also tested and were found to be carriers of 
the same mutation. 
Further clinical examination at a later stage showed 
delayed motor milestones with walking at 3 years of age. 
Today, at the age of 4 years, the index patient has diffi-
culties in walking, climbing stairs and rising up from the 
floor. He has also a symmetrical muscle weakness of up-
per and lower legs (3-4 according to MRC scale in most 
muscle groups). 
The patient’s legal representative has signed written 
informed consent for the data to be published in a scien-
tific journal. There was no need for ethical approval from 
an ethics committee, as any diagnostic step was within 
the routine management of such patients. 
Discussion
This is a report of a toddler who presented with in-
cidentally detected constantly high serum CK levels and 
was finally diagnosed with MDDS due to TK2 mutations.
The mtDNA maintenance defects, involve, basical-
ly, either the most severe mtDNA depletion syndrome 
(MDDS) or the usually milder multiple mtDNA deletion 
syndrome. MDDS is an inherited autosomal recessive 
disease, caused by a reduction of mtDNA copy number 
and as such, it may be considered as a quantitative distur-
bance, with the phenotypic severity being related to the 
remaining normal mtDNA levels 3,6. The clinical spectrum 
of the syndrome is quite diverse with variable symptoms, 
Figure 1. Transverse muscle biopsy section double 
stained with cytochromoxidase (COX) plus succinate de-
hydrogenase (SDH) – (COX-SDH x20) showing multiple 
COX-negative and SDH-positive fibers in blue. 
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mainly related to mutations in certain genes. MDDS can 
be recognized by the following prevailing phenotypes: a 
myopathic, an encephalomyopathic, a hepatocerebral and 
a neurogastrointestinal 7. 
A predominantly myopathic form, associated with 
high CK and onset in infancy or early childhood, has been 
related with TK2 mutations 7. Typically, the children de-
velop normally over the first months after birth, but they 
later lose some acquired motor milestones, usually before 
the second year of life. The most common presentations 
are hypotonia, exercise intolerance and especially proxi-
mal muscle weakness, while there may occasionally be 
some bulbar involvement with facial weakness, dysar-
thria and dysphagia  7,8. Respiratory difficulties are also 
listed high among the most frequently symptoms of the 
disease 8. Noteworthily, the ongoing recognition of new 
manifestations has expanded the phenotypic spectrum of 
TK2-related MDDS. More specifically, there may be a 
broader age range of the first symptoms with even a mild-
er adult onset presentation or a multi-organ involvement, 
including the brain with cognitive decline, epilepsy, ce-
rebral atrophy, cerebellar degeneration and diffuse white 
matter changes, the heart with cardiomyopathy, the liver 
with hepatomegaly etc. 8,9. Although, the condition has no 
approved treatment so far, there is robust evidence that 
deoxynucleoside monophosphates and deoxynucleoside 
administration may improve the clinical outcome in both 
early and late onset patients and potentially mdify the nat-
ural course of the disease 10. 
The patient of the present study is now a 4-yr old 
boy with a, so far, relatively mild pure myopathic phe-
notype. Among the initial diagnostic work-up tests, was 
the screening for deletions and duplications of the dystro-
phin gene by MLPA. After the negative results, it was not 
considered necessary, at that time, to perform sequencing 
of the gene, mainly due to a low clinical suspicion for a 
possible dystrophinopathy. The next diagnostic step was 
muscle biopsy, which revealed mitochondrial pathology 
with numerous COX-negative muscle fibers, few ragged 
red/blue fibers and myopathic changes mainly consisted 
of increased fiber size variation. The above-mentioned 
histological abnormalities, although not specific for any 
particular mitochondrial mutation, are amongst the most 
frequent features of TK2-related MDDS 11. Genetic stud-
ies revealed the already described pathogenic mutation 
c.416C > T, p.Ala139Val mutation in homozygosity, in 
the TK2 gene. 
This mutation has been firstly described in homozy-
gosity in two Greek siblings with normal early develop-
mental milestones. The older brother run a progressively 
declining course after the very first years of life, rendered 
him, at age 5 years, wheelchair-bound with severe cogni-
tive dysfunction, while her younger sister followed a rapid 
deterioration after the age of 2 years with hypotonia and 
inability to stand, six months later 5. The same mutation has 
been already reported in a compound heterozygosity in two 
affected brothers with a very severe clinical phenotype. 
Both probands were born without any sign or symptom of 
a possible underlying neuromuscular disorder, but after a 
few months of normal early development, they showed a 
rapid psychomotor regression and severe respiratory fail-
ure. The older brother suffered also from aggravating ep-
ileptic seizures and died at the age of 12 years after being 
tracheostomized for many years 4. In a more recent paper, 
there is a similar description of a young girl carrying this 
mutation in compound heterozygosity, who presented with 
Figure 2. Myoadenylate deaminase (AMPDA x40) staining from the patient showing AMPDA deficiency (A) and from 
a healthy control, with type 1 muscle fibers more intensely stained than type 2 (B).
A B
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motor skill regression at the age of 13 months and died at 
the age of 22 months after a rapid deteriorating course 9. 
Contrary to the poor outcome of the disease in all those 
affected children, the patient of the present study has run a 
more benign clinical course, so far. This discrepancy may 
reflect a lack of genotype-phenotype correlation, suggest-
ing that a possible contribution of other epigenetic or envi-
ronmental factors may determine the course of the disease. 
In any case, the existing literature based on few case re-
ports does not permit to draw general conclusions on the 
underlying genetic mechanisms. 
Moreover, an additional histological finding in the 
muscle biopsy of our patient was the absence of myoade-
nylate deaminase (AMPDA) activity. This is a quite com-
mon metabolic disturbance, estimated in approximate-
ly 2% of the population and can be coexist with other 
neuromuscular disorders. Exertional myalgia is the most 
frequently observed symptom, although most individuals 
are asymptomatic. The disorder was not genetically in-
vestigated in our patient, as it was considered coinciden-
tal, although it is difficult to determine whether AMPDA 
deficiency may partially contribute to the clinical picture, 
when combined with another metabolic disease. Howev-
er, it has been shown that even a near total AMPDA de-
ficiency does not influence exercise capacity and cellular 
energy charge, bringing into question a potential associa-
tion to an add-on effect 12. 
In conclusion, we present a paediatric patient with 
MDDS due to a homozygous pathogenic mutation in TK2 
gene, which has been already described in a homozygous 
or heterozygous state, in few severely affected patients. 
Interestingly, in addition to mitochondrial pathology, 
muscle biopsy also revealed AMPDA deficiency, which 
is a frequent histochemical abnormality and occasionally 
coexist with other metabolic disorders. We thereby ex-
pand the clinical and mutational spectrum of the TK2-re-
lated MDDS, although more cases are needed to investi-
gate genotypic correlations and whether other modifiable 
factors may contribute to phenotypic variations and dif-
fering outcomes. 
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